{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:15:13Z","timestamp":1792826113407,"version":"4.5.0"},"reference-count":59,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AG059321"],"award-info":[{"award-number":["R01AG059321"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the most common type of dementia, characterized by the abnormal accumulation of protein aggregates in the brain, known as neurofibrillary tangles and amyloid-\u03b2 (A\u03b2) plaques. It is believed that an imbalance between cerebral and peripheral pools of A\u03b2 may play a relevant role in the deposition of A\u03b2 aggregates. Therefore, in this study, we aimed to evaluate the effect of the removal of A\u03b2 from blood plasma on the accumulation of amyloid plaques in the brain. We performed monthly plasma exchange with a 5% mouse albumin solution in the APP\/PS1 mouse model from 3 to 7 months old. At the endpoint, total A\u03b2 levels were measured in the plasma, and soluble and insoluble brain fractions were analyzed using ELISA. Brains were also analyzed histologically for amyloid plaque burden, plaque size distributions, and gliosis. Our results showed a reduction in the levels of A\u03b2 in the plasma and insoluble brain fractions. Interestingly, histological analysis showed a reduction in thioflavin-S (ThS) and amyloid immunoreactivity in the cortex and hippocampus, accompanied by a change in the size distribution of amyloid plaques, and a reduction in Iba1-positive cells. Our results provide preclinical evidence supporting the relevance of targeting A\u03b2 in the periphery and reinforcing the potential use of plasma exchange as an alternative non-pharmacological strategy for slowing down AD pathogenesis.<\/jats:p>","DOI":"10.3390\/ijms242317087","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T03:40:58Z","timestamp":1701661258000},"page":"17087","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Plasma Exchange Reduces A\u03b2 Levels in Plasma and Decreases Amyloid Plaques in the Brain in a Mouse Model of Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7335-3005","authenticated-orcid":false,"given":"Santiago","family":"Ramirez","sequence":"first","affiliation":[{"name":"Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suelyn","family":"Koerich","sequence":"additional","affiliation":[{"name":"Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Astudillo","sequence":"additional","affiliation":[{"name":"Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"De Gregorio","sequence":"additional","affiliation":[{"name":"Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabab","family":"Al-Lahham","sequence":"additional","affiliation":[{"name":"Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9513-8554","authenticated-orcid":false,"given":"Tyler","family":"Allison","sequence":"additional","affiliation":[{"name":"Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Pessoa","family":"Rocha","sequence":"additional","affiliation":[{"name":"Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1798-0829","authenticated-orcid":false,"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Soto","sequence":"additional","affiliation":[{"name":"Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","article-title":"An English translation of Alzheimer\u2019s 1907 paper, \u201cUber eine eigenartige Erkankung der Hirnrinde\u201d","volume":"8","author":"Alzheimer","year":"1995","journal-title":"Clin. Anat."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"119129","DOI":"10.1016\/j.lfs.2021.119129","article-title":"A review on advances of treatment modalities for Alzheimer\u2019s disease","volume":"276","author":"Fauzi","year":"2021","journal-title":"Life Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Collaborators","year":"2022","journal-title":"Lancet Public Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer\u2019s disease facts and figures","volume":"19","author":"Association","year":"2023","journal-title":"Alzheimers Dement."},{"key":"ref_5","first-page":"a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Frosch","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00688336","article-title":"Neurofibrillary tangles in Alzheimer\u2019s disease and progressive supranuclear palsy: Antigenic similarities and differences. Microtubule-associated protein tau antigenicity is prominent in all types of tangles","volume":"74","author":"Bancher","year":"1987","journal-title":"Acta Neuropathol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ma, C., Hong, F., and Yang, S. (2022). Amyloidosis in Alzheimer\u2019s Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules, 27.","DOI":"10.3390\/molecules27041210"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and Alzheimer\u2019s disease","volume":"34","author":"Wong","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","article-title":"Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease","volume":"15","author":"Guo","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Haass, C., and Selkoe, D. (2022). If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. PLoS Biol., 20.","DOI":"10.1371\/journal.pbio.3001694"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer\u2019s Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","first-page":"197","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","author":"Aisen","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nrneurol.2016.36","article-title":"Clearance systems in the brain\u2014Implications for Alzheimer disease","volume":"12","author":"Carare","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1471-4159.2002.00889.x","article-title":"Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer\u2019s disease","volume":"81","author":"DeMattos","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","article-title":"Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer\u2019s disease","volume":"295","author":"DeMattos","year":"2002","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40035-020-00195-1","article-title":"Peripheral clearance of brain-derived Abeta in Alzheimer\u2019s disease: Pathophysiology and therapeutic perspectives","volume":"9","author":"Cheng","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","article-title":"A systemic view of Alzheimer disease\u2014Insights from amyloid-beta metabolism beyond the brain","volume":"13","author":"Wang","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-015-1477-1","article-title":"Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer\u2019s disease","volume":"130","author":"Xiang","year":"2015","journal-title":"Acta Neuropathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1038\/s41380-021-01150-w","article-title":"Transmission of cerebral amyloid pathology by peripheral administration of misfolded Abeta aggregates","volume":"26","author":"Morales","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s40478-020-01087-1","article-title":"Infusion of blood from mice displaying cerebral amyloidosis accelerates amyloid pathology in animal models of Alzheimer\u2019s disease","volume":"8","author":"Morales","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1038\/s41380-022-01679-4","article-title":"Preventive and therapeutic reduction of amyloid deposition and behavioral impairments in a model of Alzheimer\u2019s disease by whole blood exchange","volume":"27","author":"Urayama","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.2147\/NDT.S186118","article-title":"Removal of blood amyloid-beta with hemodialysis reduced brain amyloid-beta, confirmed by brain imaging: A case report","volume":"14","author":"Kitaguchi","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2147\/NDT.S241074","article-title":"Removal of Abeta Oligomers from the Blood: A Potential Therapeutic System for Alzheimer\u2019s Disease","volume":"16","author":"Saito","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00401-017-1721-y","article-title":"Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP\/PS1 mouse model","volume":"134","author":"Jin","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/JAD-160565","article-title":"Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-beta Concentrations and Cognition Outcomes in Alzheimer\u2019s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial","volume":"56","author":"Boada","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1473-0502(03)00005-3","article-title":"Therapeutic apheresis delivery systems in the US","volume":"28","author":"Kiprov","year":"2003","journal-title":"Transfus. Apher. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1744-9987.2009.00793.x","article-title":"Plasma exchange in elderly patients","volume":"14","author":"Brunetta","year":"2010","journal-title":"Ther. Apher. Dial."},{"key":"ref_30","first-page":"166","article-title":"Plasma removal with return of corpuscles (plasmaphaeresis), J Pharmacol Exp Ther Vol. V. No. 6, July, 1914","volume":"11","author":"Abel","year":"1990","journal-title":"Transfus. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.transci.2019.04.007","article-title":"Therapeutic plasma exchange: Review of current indications","volume":"58","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2014Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J. Clin. Apher."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e12004","DOI":"10.1002\/trc2.12004","article-title":"Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer\u2019s disease?","volume":"6","author":"Imbimbo","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tmrv.2022.09.005","article-title":"Plasma Exchange in Alzheimer\u2019s Disease","volume":"37","author":"Rohrer","year":"2023","journal-title":"Transfus. Med. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.1523\/JNEUROSCI.2637-09.2009","article-title":"Characterizing the appearance and growth of amyloid plaques in APP\/PS1 mice","volume":"29","author":"Yan","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/hmg\/ddh019","article-title":"Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase","volume":"13","author":"Jankowsky","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1094-9194(17)30111-1","article-title":"Clinical pathology and sample collection in the laboratory rodent","volume":"2","author":"McClure","year":"1999","journal-title":"Vet. Clin. N. Am. Exot. Anim. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cne.24555","article-title":"Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer\u2019s disease","volume":"527","author":"Whitesell","year":"2019","journal-title":"J. Comp. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","article-title":"The complement system","volume":"343","author":"Sarma","year":"2011","journal-title":"Cell Tissue Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"eaaf6295","DOI":"10.1126\/scitranslmed.aaf6295","article-title":"Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP\/PS1 mice","volume":"9","author":"Shi","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11993","DOI":"10.1073\/pnas.91.25.11993","article-title":"Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation","volume":"91","author":"Citron","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","first-page":"303","article-title":"Beta protein precursor expression in human platelets and a megakaryocyte cell line. Possible implications for the origin of cerebral amyloidosis in Alzheimer\u2019s disease","volume":"67","author":"Gardella","year":"1992","journal-title":"Lab. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1042\/bj3160671","article-title":"Apolipoprotein J and Alzheimer\u2019s amyloid beta solubility","volume":"316","author":"Matsubara","year":"1996","journal-title":"Biochem. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1006\/bbrc.2000.2222","article-title":"Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma","volume":"268","author":"Kuo","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"32916","DOI":"10.1074\/jbc.271.51.32916","article-title":"Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma","volume":"271","author":"Biere","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1089\/ars.2012.4702","article-title":"Redox albuminomics: Oxidized albumin in human diseases","volume":"17","author":"Colombo","year":"2012","journal-title":"Antioxid. Redox Signal."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103164","DOI":"10.1016\/j.transci.2021.103164","article-title":"Emerging insights into the role of albumin with plasma exchange in Alzheimer\u2019s disease management","volume":"60","author":"Costa","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/156720510790274392","article-title":"Serum albumin concentration and cognitive impairment","volume":"7","author":"Llewellyn","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13098-019-0409-y","article-title":"Reduced plasma albumin predicts type 2 diabetes and is associated with greater adipose tissue macrophage content and activation","volume":"11","author":"Chang","year":"2019","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1532-5415.1979.tb01715.x","article-title":"Reduced serum albumin concentration in the elderly: A report from the Boston Collaborative Drug Surveillance Program","volume":"27","author":"Greenblatt","year":"1979","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1212\/WNL.0000000000010005","article-title":"Serum albumin and beta-amyloid deposition in the human brain","volume":"95","author":"Kim","year":"2020","journal-title":"Neurology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3389\/fneur.2019.01036","article-title":"Albumin Exchange in Alzheimer\u2019s Disease: Might CSF Be an Alternative Route to Plasma?","volume":"10","author":"Gasparovic","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3233\/JAD-150662","article-title":"Reduction of Amyloid-beta Plasma Levels by Hemodialysis: An Anti-Amyloid Treatment Strategy?","volume":"50","author":"Tholen","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s11357-022-00645-w","article-title":"Old plasma dilution reduces human biological age: A clinical study","volume":"44","author":"Kim","year":"2022","journal-title":"Geroscience"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8790","DOI":"10.18632\/aging.103418","article-title":"Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin","volume":"12","author":"Mehdipour","year":"2020","journal-title":"Aging"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ramirez, S., Mukherjee, A., Sepulveda, S., Becerra-Calixto, A., Bravo-Vasquez, N., Gherardelli, C., Chavez, M., and Soto, C. (2021). Modeling Traumatic Brain Injury in Human Cerebral Organoids. Cells, 10.","DOI":"10.3390\/cells10102683"},{"key":"ref_57","first-page":"815361","article-title":"Aged Cattle Brain Displays Alzheimer\u2019s Disease-Like Pathology and Promotes Brain Amyloidosis in a Transgenic Animal Model","volume":"13","author":"Edwards","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1523\/JNEUROSCI.21-05-01444.2001","article-title":"Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer\u2019s disease","volume":"21","author":"Nilsson","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e18308","DOI":"10.1097\/MD.0000000000018308","article-title":"Complications of therapeutic plasma exchange: A retrospective study of 1201 procedures in 435 children","volume":"98","author":"Lu","year":"2019","journal-title":"Medicine"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/17087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:37:09Z","timestamp":1760132229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/17087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":59,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijms242317087"],"URL":"https:\/\/doi.org\/10.3390\/ijms242317087","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]}}}